GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2009

Unizyme and SARomics Ink Drug Discovery Deal for Inflammatory Diseases

  • Unizyme Laboratories in Denmark and SARomics in Sweden entered a research service collaboration related to inflammatory diseases. The aim is to discover novel lead compounds targeting dipeptidyl peptidase I (DPPI; cathepsin C).

    Unizyme will focus on identifying new small molecules that interact with and inhibit the function of DPPI. SARomics will apply its expertise in structure-based drug design to assist in the development of lead compounds.

    SARomics will also facilitate the interpretation of 3-D structures of DPPI interacting with small molecules provided by Unizyme. This information will be combined with high-speed computational methods, like high-performance ligand-receptor docking, to accelerate lead molecule identification.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »